Chemoprevention of lung cancers: Lessons from CARET, the beta-carotene and retinol efficacy trial, and prospects for the future

European Journal of Cancer Prevention

Volumn 16, Issue 3, 2007, Pages 184-191

  Omenn, Gilbert S ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

carotene; carotene and retinol efficacy trial; Alpha tocopherol (vitamin E); Beta carotene trial; Chemoprevention; Cyclooxygenase and lipoxygenase inhibitors; Israel; Retinoids

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; BETA CAROTENE; CAROTENOID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ISOTRETINOIN; LIPOXYGENASE INHIBITOR; MINERAL; NONSTEROID ANTIINFLAMMATORY AGENT; OCTREOTIDE; PHOSPHOTRANSFERASE INHIBITOR; PLACEBO; RETINOIC ACID; RETINOL; RETINOL PALMITATE; ROFECOXIB; TAMOXIFEN;

CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COLON POLYP; DIETARY INTAKE; DRUG EFFICACY; HEALTH BEHAVIOR; HUMAN; LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SMOKING; UNSPECIFIED SIDE EFFECT; VITAMIN SUPPLEMENTATION;

ANTICARCINOGENIC AGENTS; BETA CAROTENE; CHEMOPREVENTION; CLINICAL TRIALS; HUMANS; LUNG NEOPLASMS; VITAMIN A;

EID: 34247132262     PISSN: 09598278     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cej.0000215612.98132.18     Document Type: Review

References (32)

1. Alberts DS, Martinez ME, Roe DJ, Guillen-Rodriguez JM, Marshall JR, van Leeuwen JB, et al. (2000). Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. N Engl J Med 342:1156-1162.
2. Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study Group (ATBC) (1994). The effect of vitamin E and beta-carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 330:1029-1035.
3. Bairati I, Meyer F, Gelinas M, Fortin A, Nabid A, Brochet F, et al. (2005). A randomized trial of antioxidant vitamins to prevent second primary cancers in head and neck cancer patients. J Natl Cancer Inst 97:481-486.
4. Beer DG, Kardia SLR, Huang C-C, Ghafoor A, Samuels A, Ward E, et al. (2002). Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 8:816-824.
5. Bowen DJ, Thornquist M, Anderson K, Barnett M, Powell C, Goodman G, Omenn GS (2003). Stopping the active intervention: CARET. Controlled Clin Trials 24:39-50.
6. Freedman LS, Barchana M, Al-Kayed S, Qasem MB, Young JL, Edwards BK, et al. (2003). A comparison of population-based cancer incidence rates in Israel, and Jordan. Eur J Cancer Prev 12:359-365.
7. Goodman GE, Thornquist MD, Balmes J, Cullen MR, Meyskens FL Jr, Omenn GS et al. (2004). The beta-carotene and retinol efficacy trial: incidence of lung cancer and cardiovascular disease mortality during 6-year follow-up after stopping beta-carotene and retinol supplements. J Natl Cancer Inst 96:1743-1750.
8. Greenwald P (2002). Cancer prevention clinical trials. J Clin Oncol 20:14s-22s.
9. Hirsch FR, Lippman SM (2005). Advances in the biology of lung cancer chemoprevention. J Clin Oncol 23:3186-3197.
10. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans (2004). Tobacco smoke and involuntary smoking. Vol. 83. Lyon, France: WHO/ International Agency for Research on Cancer.1452pp.
11. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, et al. (2004). Cancer statistics, 2004. CA Cancer J Clin 54:8-29.
12. Keith RL, Miller YE (2005). Lung cancer: genetics of risk and advances in chemoprevention. Curr Opin Pulm Med 11:265-271.
13. Kim ES, Hong WK (2005). An apple a day "..." does it really keep the doctor away? The current state of cancer chemoprevention. J Natl Cancer Inst 97:468-470.
14. McCormick DL, Burns FJ, Albert RE (1980). Inhibition of rat mammary carcinogenesis by short dietary exposure to retinyl acetate. Cancer Res 40:1140-1143.
15. Omenn GS (1998). Chemoprevention of lung cancer: the rise and demise of beta carotene. Ann Rev Public Health 19:73-99.
16. Omenn GS (2004a). Cancer prevention, chapter 190. In: Goldman L, Ausiello D, editors. Cecil textbook of medicine. 22 ed. Philadelphia, PA: W.B. Saunders. pp. 1134-1137.
17. Omenn GS (2004b). Human lung cancer chemoprevention strategies: Parker B. Francis Lecture. Chest 125:123S-127S.
18. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, et al. (1996a). Effects of a combination of β-carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 334:1150- 1155.
19. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, et al. (1996b). Risk factors for lung cancer and for intervention effects in CARET, the beta-carotene and retinol efficacy trial. J Natl Cancer Inst 88:1550-1559.
20. Peto R, Doll R, Buckley JD, Sporn MB (1981). Can dietary beta-carotene materially reduce human cancer rates? Nature 290:201-208.
21. Raju J, Swamy MV, Cooma I, Patlolla JMR, Pittman B, Reddy BS, et al. (2005). Low doses of beta-carotene and lutein inhibit AOM-induced rat colonic ACF formation but high doses augment ACF incidence. Int J Cancer 113:798-802.
22. Saffiotti U, Montesano R, Sellakumar AR, Borg SA (1967). Experimental cancer of the lung. Inhibition by vitamin A of the induction of tracheo-bronchial squamous metaplasia and squamous cell tumors. Cancer 20:857-864.
23. Salgo MG, Cueto R, Winston GW, Pryor W (1999). Beta carotene and its oxidation products have different effects on microsome mediated binding of benzo[a]pyrene to DNA. Free Radic Biol Med 26:162-173.
24. Sporn MB, Dunlop NM, Newton DL, Smith JM. (1976). Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs [retinoids]. Fed Proc 35:1332-1338.
25. Steele VE, Hawk ET, Viner JL, Lubet RA (2003). Mechanisms and applications of non-steroidal anti-inflammatory drugs in the chemoprevention of cancer. Mutat Res 523:137-144.
26. Subbaramaiah K, Dannenberg AJ (2003). Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci 24:96-102.
27. Thornquist M, Omenn GS, Goodman GE, Grizzle J, Rosenstock L, Barnhart S, et al. (1993). Statistical design of the carotene and retinol efficacy trial (CARET). Controlled Clin Trials 14:308-324.
28. Thornquist MD, Edelstein C, Goodman GE, Omenn GS (2002). Streamlining IRB review in multisite trials through single-study IRB Cooperative Agreements: experience of the β-Carotene and Retinol Efficacy Trial (CARET). Controlled Clin Trials 23:80-86.
29. Tornwall ME, Virtamo J, Korhonen PA, Virtanen MJ, Taylor PR, Albanes D, et al. (2004). Effect of alpha-tocopherol and beta-carotene supplementation on coronary heart disease during the 6-year post-trial follow-up in the ATBC study. Eur Heart J 25:1171-1178.
30. Virtamo J, Pietinen P, Huttunen JK, Korhonen P, Malila N, Virtanen MJ, et al. (ATBC Study Group) (2003). Incidence of cancer and mortality following alpha-tocopherol and beta-carotene supplementation: a post-intervention follow-up. JAMA 290:476-485.
31. Wang XD, Liu C, Bronson RT, Smith DE, Krinsky NI, Russell M (1999). Retinoid signaling and activator protein-1 expression in ferrets given beta-carotene supplements and exposed to tobacco smoke. J Natl Cancer Inst 91:60-66.
32. Willis DB, Colburn NH (2002). Molecular targets for cancer prevention: a meeting review of the third American Cancer Society Schilling Research Conference. Cancer Epidemiol Biomarkers Prev 11:972-978.